TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37750558

Group type: EXPERIMENTAL
Intervention: Wrist-worn device with lead-I ECG and continuous photoplethysmography (Verily Study Watch)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Photoplethysmography-derived AF burden estimation
Number of subjects: 117

Group type: COMPARATOR
Intervention: 14-day continuous ECG monitor (Zio XT)
Number of subjects: 117
Study: 37750588

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 128
Study: 37750660

Group type: EXPERIMENTAL
Intervention: Sequential exercise-cognitive training (SEQ)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dual-task exercise-cognitive training (DUAL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 63
Study: 37750695

Group type: EXPERIMENTAL
Intervention: Oral tedizolid treatment for BJIs
Number of subjects: 44
Study: 37750771

Group type: EXPERIMENTAL
Intervention: BPE extent quantified using fully automated software
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Tertiles of BPE, FGT volume, and fat volume
Number of subjects: 1476
Study: 37750774

Group type: EXPERIMENTAL
Intervention: Deep learning (DL) reconstruction of low-resolution T2-weighted turbo spin-echo (TSE) prostate MRI scans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-resolution T2-weighted TSE sequence
Number of subjects: 0
Study: 37750994

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks, with possible uptitration to 200 or 300 mg every 2 weeks based on weight and IGA score.
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment reinitiated after stopping due to achieving clear/almost clear skin.
Number of subjects: 321
Study: 37750995

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 199
Study: 37751016

Group type: EXPERIMENTAL
Intervention: Gepotidacin (2 × 3000 mg 10-12 h apart)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Ceftriaxone (500 mg, intramuscular) plus Azithromycin (1 g, oral)
Number of subjects: 400
Study: 37751015

Group type: EXPERIMENTAL
Intervention: AZD7442 (600 mg)
Number of subjects: 903

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study: 37751019

Group type: EXPERIMENTAL
Intervention: Fostemsavir + Optimized Background Therapy (OBT)
Number of subjects: 0
Study: 37751022

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37751113

Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 0
Study: 37751153

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable glucagon administration
Number of subjects: 0
Study: 37751186

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interaction
Number of subjects: 0
Study: 37751207

Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 2591
Study: 37751237

Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs) with notifications delivered up to 4 times per day and suggested daily step goals
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Notifications to walk based on JIT states considering need, opportunity, and receptivity
Number of subjects: 48
Study: 37751247

Group type: EXPERIMENTAL
Intervention: H-Coaching programme for nurses
Number of subjects: 0
Study: 37751286

Group type: EXPERIMENTAL
Intervention: Mindfulness Treatment (MT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 29
Study: 37751301

Group type: EXPERIMENTAL
Intervention: Exendin 9-39 (GLP-1 Receptor antagonist)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 2
Study: 37751376

Group type: EXPERIMENTAL
Intervention: HPV DNA testing with selective 16/18 genotyping
Number of subjects: 2409

Group type: EXPERIMENTAL
Intervention: Dual staining cytology
Number of subjects: 2409
Study: 37751429

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) and patient portal
Number of subjects: 856

Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: CDSS and patient portal
Number of subjects: 856
Study: 37751455

Group type: EXPERIMENTAL
Intervention: CDC algorithm for COVID-19-related admissions
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Massachusetts classification for COVID-19-related admissions
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Patients hospitalized for COVID-19
Number of subjects: 1651
Study: 37751561

Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg orally twice daily) and Trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tucatinib and Trastuzumab
Number of subjects: 30
Study: 37751891

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir 100 mg with ritonavir 100 mg administered 12 hours before, together with, and 12 and 24 hours after nirmatrelvir
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Number of subjects: 16
Study: 37751948

Group type: EXPERIMENTAL
Intervention: Regional radiotherapy (RT) including the axilla level I-III, supraclavicular fossa, and internal mammary nodes in selected patients. Chest-wall RT after mastectomy is given only in cases of widespread multifocality according to national guidelines.
Number of subjects: 1350

Group type: COMPARATOR
Intervention: No regional radiotherapy (intervention arm).
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Regional RT (standard arm)
Number of subjects: 1350
Study: 37751953

Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 120
Study: 37751961

Group type: EXPERIMENTAL
Intervention: Patients with ocular pain (36 patients, 72 eyes)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Patients without ocular pain (26 patients, 52 eyes)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Corneal nerve fibre density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fibre length (CNFL)
Number of subjects: 62
Study: 37752337

Group type: EXPERIMENTAL
Intervention: Diaphragm dysfunction assessment on Day 1 of ECMO initiation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diaphragm function assessment over time
Number of subjects: 63
Study: 37752344

Group type: EXPERIMENTAL
Intervention: 4DM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4DM-FVD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cedars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emory-Votaw
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emory-Ottawa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HeartSee
Number of subjects: 0
Study: 37752365

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS) before extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surface available for ventilation before extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Global inhomogeneity index (GI index) after extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lung ultrasound score (LUS) after extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surface available for ventilation after extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Regional ventilation delay (RVD) after extubation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Center of ventilation (CoV) after extubation
Number of subjects: 40
Study: 37752379

Group type: EXPERIMENTAL
Intervention: Blood donation (mild acute blood loss)
Number of subjects: 26
Study: 37752423

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg/day continuously plus lanreotide 120 mg every 28 days
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus lanreotide
Number of subjects: 69
Study: 37752426

Group type: EXPERIMENTAL
Intervention: Protein, omega-3 supplementation, and physical exercise program
Number of subjects: 200
Study: 37752447

Group type: EXPERIMENTAL
Intervention: 15-week dietary intervention combined with behaviour change techniques guided by the Health Action Process Approach model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular health talks
Number of subjects: 60
Study: 37752466

Group type: EXPERIMENTAL
Intervention: Dietary treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 29
Study: 37752480

Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 37752531

Group type: EXPERIMENTAL
Intervention: Kid Gaze Rehab (KGR) combined with traditional vestibular rehabilitation
Number of subjects: 12
Study: 37752564

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (remotely guided) with an educational component about cancer and exercise.
Number of subjects: 80
Study: 37752566

Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg/d) for 26 weeks in LiraFlame26 trial
Number of subjects: 129

Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg/d) for 12 weeks in LirAlbu12 trial
Number of subjects: 129
Study: 37752607

Group type: EXPERIMENTAL
Intervention: Reinforcement Learning (RL) algorithm for neurostimulation parameters
Number of subjects: 54

Group type: COMPARATOR
Intervention: Brute Force Algorithm (BFA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Naïve approach
Number of subjects: 54

Group type: COMPARATOR
Intervention: Trained experimenters
Number of subjects: 54
Study: 37752621

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 37752816

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified four-drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C)
Number of subjects: 0
Study: 37752878

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 0
Study: 37752882

Group type: EXPERIMENTAL
Intervention: Tailored community communication campaigns
Number of subjects: 66
Study: 37752892

Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 652

Group type: COMPARATOR
Intervention: ibrutinib
Number of subjects: 652
Study: 37753225

Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 4395

Group type: COMPARATOR
Intervention: 4-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 4395
Study: 37753336

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37753340

Group type: EXPERIMENTAL
Intervention: Modified blood collection method
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional blood collection method
Number of subjects: 92
Study: 37753443

Group type: EXPERIMENTAL
Intervention: E-cigarette group (received a free 4-week supply of flavoured, tank-style e-cigarette)
Number of subjects: 638

Group type: COMPARATOR
Intervention: No-product control group
Number of subjects: 638
Study: 37753461

Group type: EXPERIMENTAL
Intervention: Adaptive FDG-PET/CT response-guided radiotherapy (total dose 70-78 Gy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard 70 Gy radiotherapy (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adaptive FDG-PET/CT response-guided radiotherapy
Number of subjects: 20
Study: 37753446

Group type: COMPARATOR
Intervention: Oral anticoagulant (OAC) prescription
Number of subjects: 34421

Group type: COMPARATOR
Intervention: Non-vitamin K antagonist oral anticoagulant (NOAC) prescription
Number of subjects: 34421

Group type: COMPARATOR
Intervention: OAC discontinuation
Number of subjects: 34421

Group type: COMPARATOR
Intervention: Primary composite outcome (all-cause death and major adverse cardiovascular events)
Number of subjects: 34421

Group type: EXPERIMENTAL
Intervention: Thromboembolism risk
Number of subjects: 34421

Group type: EXPERIMENTAL
Intervention: Intracranial haemorrhage risk
Number of subjects: 34421

Group type: EXPERIMENTAL
Intervention: Major bleeding risk
Number of subjects: 34421
Study: 37753640

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores and targeted proteomics added to PROMISE minimal risk score (PMRS)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: PROMISE minimal risk score (PMRS) alone
Number of subjects: 1440
Study: 37753702

Group type: EXPERIMENTAL
Intervention: NALIRIFOX (liposomal irinotecan with 5-FU and oxaliplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRINOX (nonliposomal irinotecan with 5-FU and oxaliplatin)
Number of subjects: 0
Study: 37753718

Group type: EXPERIMENTAL
Intervention: Etripamil nasal spray
Number of subjects: 169
Study: 37753808

Group type: EXPERIMENTAL
Intervention: TPMT-NUDT15 gene-based dosing of 6-MP (10 to 50 mg/m2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (standard dosing of 6-MP)
Number of subjects: 44
Study: 37753954

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 12
Study: 37753960

Group type: EXPERIMENTAL
Intervention: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd)
Number of subjects: 125
Study: 37754204

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 390

Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 390
Study: 37754283

Group type: EXPERIMENTAL
Intervention: Tight glucose control (blood-glucose level targeted at 80 to 110 mg per deciliter)
Number of subjects: 9230

Group type: COMPARATOR
Intervention: Liberal glucose control (insulin initiated only when blood-glucose level was >215 mg per deciliter)
Number of subjects: 9230

Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 9230

Group type: COMPARATOR
Intervention: Liberal glucose control
Number of subjects: 9230
Study: 37754485

Group type: EXPERIMENTAL
Intervention: Camu camu (CC) added to nivolumab
Number of subjects: 2
Study: 37754491

Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation Guided Transperineal Fiducial Markers Implantation Technique
Number of subjects: 1
Study: 37754571

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 93797

Group type: EXPERIMENTAL
Intervention: Cancer-specific mortality
Number of subjects: 93797

Group type: EXPERIMENTAL
Intervention: Older patients (≥60 years)
Number of subjects: 93797

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 93797
Study: 37754682

Group type: EXPERIMENTAL
Intervention: Prenatal malaria exposure (PME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibodies at birth
Number of subjects: 0
Study: 37755151

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) treatment, 12 sessions
Number of subjects: 34
Study: 37755371

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Nasojejunal early enteral nutrition (NJEEN)
Number of subjects: 428
Study: 37755506

Group type: EXPERIMENTAL
Intervention: Bleach baths (0.005% NaClO; 5-10 min duration) twice a week for 12 weeks
Number of subjects: 15
Study: 37755689

Group type: EXPERIMENTAL
Intervention: PASI100
Number of subjects: 2701

Group type: EXPERIMENTAL
Intervention: PASI90 - < 100
Number of subjects: 2701

Group type: EXPERIMENTAL
Intervention: PASI75 - < 90
Number of subjects: 2701

Group type: EXPERIMENTAL
Intervention: < PASI75
Number of subjects: 2701
Study: 37755833

Group type: EXPERIMENTAL
Intervention: Technology-assisted buprenorphine (TAB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (community resource guides and assistance)
Number of subjects: 100
Study: 37755958

Group type: COMPARATOR
Intervention: onaBoNT-A (Cohort 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: aboBoNT-A (Cohort 2)
Number of subjects: 114
Study: 37755979

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 834
Study: 37756047

Group type: EXPERIMENTAL
Intervention: Woebot LIFE (WB-LIFE) digital mental health intervention
Number of subjects: 255
Study: 37756123

Group type: EXPERIMENTAL
Intervention: Long-Acting Injectable Paliperidone Palmitate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Antipsychotics
Number of subjects: 0
Study: 37756299

Group type: COMPARATOR
Intervention: Omicron variant infection
Number of subjects: 35806

Group type: COMPARATOR
Intervention: Wild-type/delta variant infection
Number of subjects: 35806

Group type: COMPARATOR
Intervention: Influenza infection
Number of subjects: 35806

Group type: EXPERIMENTAL
Intervention: Age 80 years vs. age 50 years
Number of subjects: 35806

Group type: EXPERIMENTAL
Intervention: Wild-type/delta variant infection vs. influenza infection
Number of subjects: 35806

Group type: EXPERIMENTAL
Intervention: Omicron variant infection vs. influenza infection
Number of subjects: 35806
Study: 37756321

Group type: EXPERIMENTAL
Intervention: e-registration tracking system and mHealth counseling
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group (no e-registration and mHealth counseling)
Number of subjects: 536
Study: 37756532

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M) 560 mg daily for up to 4 years
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M)
Number of subjects: 36
Study: 37757502

Group type: EXPERIMENTAL
Intervention: Specialized oral nutritional supplement (S-ONS)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 622
Study: 37757520

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Ticagrelor or Clopidogrel
Number of subjects: 800
Study: 37757587

Group type: EXPERIMENTAL
Intervention: Older patients (≥70 years old)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 157
Study: 37757844

Group type: EXPERIMENTAL
Intervention: Patient-centered counseling with participant-selected adherence supporter
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard counseling (control)
Number of subjects: 200
Study: 37757868

Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age categories
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age sensitivity
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age specificity
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Subgroup analyses for various parent and socioeconomic factors
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Factors associated with lower sensitivity and/or specificity
Number of subjects: 4684
Study: 37757873

Group type: EXPERIMENTAL
Intervention: Capture-recapture approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian model
Number of subjects: 0
Study: 37757880

Group type: EXPERIMENTAL
Intervention: Community mobilization approach
Number of subjects: 396

Group type: COMPARATOR
Intervention: House-to-house approach
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Community mobilization approach in multiple-visit villages
Number of subjects: 396

Group type: COMPARATOR
Intervention: House-to-house approach in multiple-visit villages
Number of subjects: 396
Study: 37757966

Group type: EXPERIMENTAL
Intervention: Glycated serum proteins
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: GA/HbA1c ratio
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 334
Study: 37758507

Group type: EXPERIMENTAL
Intervention: Fluobeam® LX
Number of subjects: 535

Group type: COMPARATOR
Intervention: Control (no use of Fluobeam® LX)
Number of subjects: 535
Study: 37758574

Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance therapy (intravenous nivolumab 8 × 240 mg every 2 weeks, followed by 480 mg every 4 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitor (TKI) maintenance therapy (sunitinib 50 mg or pazopanib 800 mg once daily)
Number of subjects: 49
Study: 37758623

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Thoracic epidural bupivacaine with morphine
Number of subjects: 210
Study: 37758649

Group type: EXPERIMENTAL
Intervention: Community-based adherence support intervention for daily oral PrEP
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Community-based PrEP delivery platform and behavioural intervention
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Long-acting injectable PrEP
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Interventions integrating long-term planning skills and social support
Number of subjects: 603
Study: 37758676

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) combined with conventional treatment, 9 sessions (1 session/week for 9 weeks), each lasting 30-40 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (pharmacological treatment)
Number of subjects: 80
Study: 37758678

Group type: EXPERIMENTAL
Intervention: Questionnaires assessing anxiety, depression, post-traumatic stress symptoms, health-related quality of life and physical symptoms at 3, 6 and/or 12 months after ICU discharge
Number of subjects: 0
Study: 37758711

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clonal evolution analysis of longitudinally collected tumour samples
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pre-treatment immunogenicity analysis
Number of subjects: 22
Study: 37758864

Group type: EXPERIMENTAL
Intervention: Differential platelet/endothelial activation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture positive sepsis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture negative sepsis with 5 days of antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non sepsis
Number of subjects: 0